Tricuspid regurgitation laboratory findings: Difference between revisions
| Line 21: | Line 21: | ||
OR | OR | ||
There are no diagnostic laboratory findings associated with [ | There are no diagnostic laboratory findings associated with [[tricuspid regurgitation]]. | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
There are no diagnostic laboratory findings associated with [ | There are no diagnostic laboratory findings associated with [[tricuspid regurgitation]]. | ||
OR | OR | ||
| Line 39: | Line 39: | ||
Laboratory findings consistent with the diagnosis of [disease name] include: | Laboratory findings consistent with the diagnosis of [disease name] include: | ||
[[Biomarkers]] can predict the [[cardiovascular]] complications in [[pregnancy]] and the following can be used to elevate: | [[Biomarkers]] can predict the [[cardiovascular]] complications in [[pregnancy]] and the following can be used to elevate:<ref name="pmid20883932">{{cite journal| author=Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD | display-authors=etal| title=B-type natriuretic peptide in pregnant women with heart disease. | journal=J Am Coll Cardiol | year= 2010 | volume= 56 | issue= 15 | pages= 1247-53 | pmid=20883932 | doi=10.1016/j.jacc.2010.02.076 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20883932 }}</ref> | ||
* N-terminal pro-B-type [[Natriuretic peptides|natriuretic peptide]] | * N-terminal pro-B-type [[Natriuretic peptides|natriuretic peptide]] | ||
Revision as of 15:01, 5 May 2020
|
Tricuspid Regurgitation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tricuspid regurgitation laboratory findings On the Web |
|
American Roentgen Ray Society Images of Tricuspid regurgitation laboratory findings |
|
Risk calculators and risk factors for Tricuspid regurgitation laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with tricuspid regurgitation.
Laboratory Findings
There are no diagnostic laboratory findings associated with tricuspid regurgitation.
OR
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
[Test] is usually normal among patients with [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include:
Biomarkers can predict the cardiovascular complications in pregnancy and the following can be used to elevate:[1]
- N-terminal pro-B-type natriuretic peptide
- B-type natriuretic peptide
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
References
- ↑ Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD; et al. (2010). "B-type natriuretic peptide in pregnant women with heart disease". J Am Coll Cardiol. 56 (15): 1247–53. doi:10.1016/j.jacc.2010.02.076. PMID 20883932.